The Journal of Urology
Volume 182, Issue 6, Supplement , Pages S45-S50, December 2009

Diabetes, Obesity and Erectile Dysfunction: Field Overview and Research Priorities

  • Kanchan Chitaley
  • ,
  • Varant Kupelian
  • ,
  • Leslee Subak
  • ,
  • Hunter Wessells

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Urology, University of Washington, 1959 Pacific Ave. Northeast, Box 356510, Seattle, Washington 98104 (telephone: 206-731-3205; FAX: 206-731-4709)
    • Financial interest and/or other relationship with PNN Medical and American Medical Systems.

Department of Urology, University of Washington School of Medicine, Seattle, Washington, New England Research Institutes, Watertown, Massachusetts, and Departments of Obstetrics, Gynecology and Reproductive Science, Urology and Epidemiology, University of California-San Francisco, San Francisco, California

published online 20 October 2009.

Purpose

We provide an overview of basic, clinical and epidemiological research in the field of erectile dysfunction and important research priorities presented at the 2009 National Institute of Diabetes and Digestive and Kidney Diseases symposium on Urological Complications of Diabetes and Obesity.

Materials and Methods

Experts in molecular biology, physiology, pharmacology, clinical trials, epidemiology and urological surgery highlighted current knowledge on erectile dysfunction associated with diabetes mellitus and obesity.

Results

Predictable associations between erectile dysfunction, and poor diabetic control and modifiable risk factors, including body mass index, have not yet been translated into randomized trials in the United States. The relationship between erectile dysfunction and metabolic syndrome, and surrogate markers for erectile dysfunction requires further investigation. Basic research aimed at discovering disease mechanisms and therapeutic targets has focused on autonomic neuropathy, vascular dysfunction, smooth muscle contractile function and matrix. However, significant gaps exist in regard to the integration of molecular, cellular and functional data. Animal models of type 2 diabetes and obesity associated erectile dysfunction require investigation because most basic science studies have used rodent models of type 1 diabetes.

Conclusions

Studies are needed to synthesize a systems biology understanding of erectile function/dysfunction, and characterize and disseminate rodent models of erectile dysfunction associated with type 2 diabetes and obesity. Clinical studies are needed of promising intervention and prevention strategies. Leveraging existing and future cohort phenotypes, and biological samples is needed for risk factor analysis, biomarker discovery and genome wide association studies.

Key Words: penis, impotence, diabetes, obesity, epidemiology

Abbreviations and Acronyms: BMI, body mass index, CRP, C-reactive protein, ED, erectile dysfunction, IIEF, International Index of Erectile Function domain, IIEF-EF, IIEF-erectile function, MMAS, Massachusetts Male Aging Study, NO, nitric oxide, PDE5-I, phosphodiesterase type 5 inhibitor, T1D, type 1 diabetes, T2D, type 2 diabetes, ZDF, Zucker rat

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0022-5347(09)01946-6

doi:10.1016/j.juro.2009.07.089

The Journal of Urology
Volume 182, Issue 6, Supplement , Pages S45-S50, December 2009